Ocular Therapeutix (NASDAQ:OCUL) Hits New 52-Week Low - What's Next?

Ocular Therapeutix logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ocular Therapeutix shares hit a 52-week low, falling to $5.78 intraday and last trading at $5.834, below the prior close of $5.94.
  • Analyst opinion is mostly positive: the stock has a “Moderate Buy” consensus and an average price target of $23.83, though ratings range from Strong Buy to Sell.
  • The company’s latest quarter missed expectations, reporting an adjusted loss of $0.42 per share versus the $0.36 expected and revenue of $12.87 million versus estimates of $14.27 million; revenue fell 11.5% year over year.
  • MarketBeat previews top five stocks to own in December.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report)'s share price hit a new 52-week low on Thursday. The stock traded as low as $5.78 and last traded at $5.8340, with a volume of 614,997 shares traded. The stock had previously closed at $5.94.

Analysts Set New Price Targets

Several equities analysts have recently commented on OCUL shares. Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Needham & Company LLC restated a "buy" rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a report on Monday, October 19th. Chardan Capital reiterated a "buy" rating and issued a $23.00 price target on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Royal Bank Of Canada restated an "outperform" rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Ocular Therapeutix in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $23.83.

View Our Latest Stock Report on OCUL

Ocular Therapeutix Stock Down 1.6%

The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.05 and a current ratio of 9.12. The company has a market capitalization of $1.29 billion, a PE ratio of -4.01 and a beta of 1.22. The firm's 50-day simple moving average is $7.68 and its 200 day simple moving average is $8.85.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.06). The company had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.27 million. Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. Ocular Therapeutix's revenue was down 11.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.38) earnings per share. As a group, equities research analysts forecast that Ocular Therapeutix, Inc. will post -1.61 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Pravin Dugel sold 21,649 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $10.77, for a total transaction of $233,159.73. Following the sale, the insider owned 2,525,429 shares of the company's stock, valued at $27,198,870.33. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Namrata Saroj sold 35,370 shares of Ocular Therapeutix stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $6.55, for a total transaction of $231,673.50. Following the sale, the insider owned 220,522 shares of the company's stock, valued at approximately $1,444,419.10. This trade represents a 13.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 98,090 shares of company stock valued at $787,920. 3.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors have recently added to or reduced their stakes in OCUL. Deltec Asset Management LLC increased its position in shares of Ocular Therapeutix by 6.0% during the third quarter. Deltec Asset Management LLC now owns 2,623,597 shares of the biopharmaceutical company's stock worth $20,123,000 after acquiring an additional 147,400 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Ocular Therapeutix during the second quarter worth $5,099,000. Dimensional Fund Advisors LP bought a new position in Ocular Therapeutix in the first quarter worth about $5,491,000. The Manufacturers Life Insurance Company boosted its position in Ocular Therapeutix by 145.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 227,808 shares of the biopharmaceutical company's stock valued at $1,930,000 after purchasing an additional 135,160 shares during the period. Finally, Second Line Capital LLC increased its holdings in shares of Ocular Therapeutix by 20.9% in the 2nd quarter. Second Line Capital LLC now owns 638,640 shares of the biopharmaceutical company's stock worth $6,271,000 after acquiring an additional 110,350 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ocular Therapeutix Right Now?

Before you consider Ocular Therapeutix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.

While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines